GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
N. Meningitidis Carriage Study
- Conditions
- Infections, Meningococcal
- Interventions
- Procedure: Posterior pharyngeal swabOther: Data collection
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1000
- Registration Number
- NCT01808365
- Locations
- 🇵🇭
GSK Investigational Site, Manila, Philippines
To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT01808339
- Locations
- 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia
Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 134
- Registration Number
- NCT01808313
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
A Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers
- Conditions
- Infections, Bacterial
- Interventions
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2015-01-28
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01803399
Single Dose Escalation Study of GSK2838232 in Healthy Subjects
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 17
- Registration Number
- NCT01802918
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Post-marketing Safety Study of GlaxoSmithKline (GSK) Biologicals' Synflorix™ Vaccine, in Healthy Infants and Children in Sri Lanka
- Conditions
- Immunisation Against Streptococcus Pneumoniae
- Interventions
- Other: Synflorix™ data collection
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2013-09-09
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01803425
GSK239512 DDI Study
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 22
- Registration Number
- NCT01802931
- Locations
- 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia
Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret)
- Conditions
- Transplantation, Stem Cell
- Interventions
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT01802892
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy
- Conditions
- Herpes ZosterHerpes Zoster Vaccine
- Interventions
- Biological: GSK 1437173ADrug: Placebo
- First Posted Date
- 2013-02-25
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 237
- Registration Number
- NCT01798056
- Locations
- 🇬🇧
GSK Investigational Site, York, United Kingdom
Study to Determine the Bioequivalence of Two Fixed Dose Combination (FDC) Tablet Formulations of Amlodipine and Losartan FDC5/50 and FDC5/100 Under Fasting Conditions
- Conditions
- Hypertension
- Interventions
- Drug: FDC 5/50 amlodipine/ losartan
- First Posted Date
- 2013-02-25
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 102
- Registration Number
- NCT01797926
- Locations
- 🇿🇦
GSK Investigational Site, Bloemfontein,, South Africa